YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
GSK (LSE:GSK) has entered a collaboration with Wave Life Sciences to advance a GalNAc-siRNA hepatology candidate into its development pipeline. The partnership with Wave Life Sciences focuses on RNA-based therapies targeting liver diseases…
Fresh funding from the Gates Foundation for AN2 Therapeutics' tuberculosis collaboration with GSK (LSE:GSK) has put the pharma group's boron based LeuRS inhibitor program back in focus for investors. The GSK share price has softened in the…
Abstracts highlight epetraborole's potential beneficial effects on hematological profile across clinical and nonclinical studies MENLO PARK, Calif., August 31, 2026--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage…
MENLO PARK, Calif., May 07, 2026--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, C…
* Clinical-stage biopharmaceutical company AN2 Therapeutics (ANTX [https://seekingalpha.com/symbol/ANTX]) announced [https://seekingalpha.com/pr/20428536-an2-therapeutics-announces-40-million-private-placement-financing] a $40M private pla…
* AN2 Therapeutics press release [https://seekingalpha.com/pr/20304970-an2-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-and] (ANTX [https://seekingalpha.com/symbol/ANTX]): Q3 net loss was $9.4 million. * Th…
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases, finds itself at a critical juncture following recent clinical trial results and strategi…
* AN2 Therapeutics press release [https://seekingalpha.com/pr/20198548-an2-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-and] (NASDAQ:ANTX [https://seekingalpha.com/symbol/ANTX]): Q2 GAAP EPS of -$0.21 beat…
In this piece, we will take a look at the 13 best falling stocks to buy now. If you want to skip our coverage of the latest stock market news, then you can take a look at the 5 Best Falling Stocks To Buy Right Now. The start of the year ha…
U.S. Enrollment Ongoing in EBO-301 Pivotal Phase 2/3 Clinical Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Plan to Include Japanese Patients in Trial Awarded Contract from NIAID Valued Up to $17.8 Million to Advance Deve…
MENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet nee…
Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung Disease MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company…
Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese Patients Treatment-Refractory MAC Lung Disease Clinical Development Strategy to Focus Initially on Japan and U…
Non-dilutive funding will drive synergies with existing epetraborole development program for NTM lung disease Award leverages AN2 Therapeutics expertise and commitment to address urgent unmet global health needsWork could help address U.S.…
MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet nee…
Enrolling U.S. Patients in the EBO-301 Pivotal Phase 2/3 Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Topline Results from Phase 2 Part of Trial Expected in Mid-2023 Completed Enrollment in Phase 1 PK/Safety Study of Epe…
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an initial focus on treatment-refractory MAC lung disease Phase 2/3 pivotal trial expec…
On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole Clinical Program with Enrollment for Pivotal Phase 2/3 Trial in Treatment-Refract…
MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today anno…